Euro-Med Laboratories Phil., Inc. (PSE: EURO)
Philippines
· Delayed Price · Currency is PHP 0.710
-0.030 (-4.05%)
Sep 9, 2024, 4:00 PM PST
EURO Income Statement
Financials in millions PHP. Fiscal year is January - December.
Millions PHP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | 5,632 | 5,264 | 4,224 | 3,587 | 3,829 | 5,688 | Upgrade
|
| Revenue Growth (YoY) | 19.42% | 24.62% | 17.75% | -6.31% | -32.68% | 9.22% | Upgrade
|
| Cost of Revenue | 3,624 | 3,370 | 2,731 | 2,150 | 2,213 | 3,559 | Upgrade
|
| Gross Profit | 2,008 | 1,894 | 1,493 | 1,438 | 1,617 | 2,129 | Upgrade
|
| Selling, General & Admin | 1,261 | 1,209 | 1,025 | 991.39 | 1,045 | 1,334 | Upgrade
|
| Other Operating Expenses | 31.25 | 32.75 | 28.03 | 35.23 | 31.06 | 34.19 | Upgrade
|
| Operating Expenses | 1,292 | 1,242 | 1,053 | 1,027 | 1,076 | 1,368 | Upgrade
|
| Operating Income | 715.67 | 652.58 | 440.44 | 411.1 | 540.72 | 760.93 | Upgrade
|
| Interest Expense | -292.18 | -270.45 | -206.8 | -213.19 | -215.36 | -253.31 | Upgrade
|
| Interest & Investment Income | 2.08 | 1.29 | 0.5 | 0.7 | 6.47 | 12.4 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.59 | 1.66 | 34.36 | -16.98 | -37.3 | -1.23 | Upgrade
|
| Other Non Operating Income (Expenses) | -2.98 | 0.09 | 12.88 | 5.85 | 6.86 | 15.37 | Upgrade
|
| EBT Excluding Unusual Items | 429.19 | 385.17 | 281.39 | 187.48 | 301.38 | 534.17 | Upgrade
|
| Gain (Loss) on Sale of Investments | 13.23 | 13.23 | -1.09 | 43.93 | 3.65 | 22.91 | Upgrade
|
| Pretax Income | 442.42 | 398.4 | 280.3 | 231.41 | 305.03 | 557.07 | Upgrade
|
| Income Tax Expense | 118.7 | 108.45 | 80.41 | 62.36 | 94.98 | 168.2 | Upgrade
|
| Net Income | 323.72 | 289.95 | 199.89 | 169.05 | 210.05 | 388.88 | Upgrade
|
| Net Income to Common | 323.72 | 289.95 | 199.89 | 169.05 | 210.05 | 388.88 | Upgrade
|
| Net Income Growth | 45.53% | 45.06% | 18.24% | -19.52% | -45.99% | 4.00% | Upgrade
|
| Shares Outstanding (Basic) | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | Upgrade
|
| Shares Outstanding (Diluted) | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | 4,112 | Upgrade
|
| EPS (Basic) | 0.08 | 0.07 | 0.05 | 0.04 | 0.05 | 0.09 | Upgrade
|
| EPS (Diluted) | 0.08 | 0.07 | 0.05 | 0.04 | 0.05 | 0.09 | Upgrade
|
| EPS Growth | 45.53% | 44.01% | 21.52% | -20.00% | -47.13% | 4.00% | Upgrade
|
| Free Cash Flow | -149.75 | 62.26 | 59.35 | 202.83 | -9.9 | 73.58 | Upgrade
|
| Free Cash Flow Per Share | -0.04 | 0.02 | 0.01 | 0.05 | -0.00 | 0.02 | Upgrade
|
| Dividend Per Share | - | - | 0.035 | 0.020 | 0.015 | 0.050 | Upgrade
|
| Dividend Growth | - | - | 75.00% | 33.33% | -70.00% | -28.57% | Upgrade
|
| Gross Margin | 35.65% | 35.98% | 35.35% | 40.08% | 42.22% | 37.43% | Upgrade
|
| Operating Margin | 12.71% | 12.40% | 10.43% | 11.46% | 14.12% | 13.38% | Upgrade
|
| Profit Margin | 5.75% | 5.51% | 4.73% | 4.71% | 5.49% | 6.84% | Upgrade
|
| Free Cash Flow Margin | -2.66% | 1.18% | 1.40% | 5.65% | -0.26% | 1.29% | Upgrade
|
| EBITDA | 951.76 | 890.72 | 664.09 | 639 | 762.97 | 1,002 | Upgrade
|
| EBITDA Margin | 16.90% | 16.92% | 15.72% | 17.81% | 19.93% | 17.61% | Upgrade
|
| D&A For EBITDA | 236.08 | 238.14 | 223.65 | 227.9 | 222.25 | 240.97 | Upgrade
|
| EBIT | 715.67 | 652.58 | 440.44 | 411.1 | 540.72 | 760.93 | Upgrade
|
| EBIT Margin | 12.71% | 12.40% | 10.43% | 11.46% | 14.12% | 13.38% | Upgrade
|
| Effective Tax Rate | 26.83% | 27.22% | 28.69% | 26.95% | 31.14% | 30.19% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.